-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Luye Pharma announced that its self-developed new compound and a new class 1 chemical drug in China-Ansufacine Hydrochloride Sustained Release Tablets (LY03005) have reached the preset end point in the Phase III clinical trial in China.
LY03005 is a serotonin-norepinephrine-dopamine triple reuptake inhibitor (SNDRI) for the treatment of depression.
The results of this phase III clinical trial show that: LY03005 is safe and effective in treating depression and can comprehensively improve depression symptoms, especially in alleviating anhedonia, improving cognitive function and not affecting sexual function.
The China Phase III clinical trial of LY03005 is a multi-center, randomized, double-blind, placebo-controlled study to verify the effectiveness and safety of LY03005 in the treatment of depression.
Note: The original text has been deleted